Mild Alzheimer’s Disease Study in patients with Glucose Intolerance (T2DM)

  • STATUS
    Not Recruiting
Updated on 12 January 2021

Summary

We are enrolling participants in a new mild Alzheimer’s clinical trial. This trial will evaluate the safety and effectiveness of the study medication, azeligaron in the treatment of mild Alzheimer’s disease in patients who also have glucose intolerance or Type 2 Diabetes: those with HGbA1c of 6.5% to 9.5%).

Study participation will last about eleven months. Following an approximate 60 day screening period, qualified participants will be randomly assigned to the study medication, azeligaron, or a placebo (an inactive substance). During the treatment period, the participants will visit the research center 2 times over a 6 month period. All participants will come back 3 months after the final study visit for a follow-up visit.

 

Description

Participants should continue on your current Alzheimer’s medication. Study-related neuro- psychological evaluation, neurological and physical exams, laboratory tests, ECG, and brain scans will be provided to research study participants at designated time points during screening and throughout the trial.

If you qualify for this research study, all research related care, evaluations, study medication, and office visits will be provided at no cost. Insurance is not required for study participation and compensation may be available.

Details
Condition Alzheimer's Disease, Diabetes Mellitus, Type 2, Memory Loss, Memory Problems, Diabetes Mellitus Type 2
Clinical Study IdentifierTX228542
Last Modified on12 January 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note